IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a private biotech pioneering cellular secretome treatments to address age and disease-related immune decline, presents a one-of-a-kind film (The Time is Now) with world-renowned longevity innovators who examine the future of aging and human healthspan. Immunis was honored to host esteemed interviewees Dr. Peter Diamandis, Dr. Hans Keirstead, Dr. Daniel Kraft, and Jane Metcalfe, who all share the common goal of revolutionizing human health.
With over 50,000 biotech companies dedicated to longevity, the opportunity to increase our healthspan is more attainable than ever before. “It’s this decade that we have the tools, both from a data and computational standpoint, [and] also from a biology standpoint,” says Dr. Diamandis. Dr. Diamandis is an esteemed leader in space exploration and innovation, who created the XPRIZE Foundation to drive revolutionary technology development and co-founded Singularity to guide future-focused education. His work with Fountain Life further showcases his commitment to extending healthy years through data-driven modeling and AI.
The world is evolving in such a way that people have more access to personalized resources for their health journey. It’s no longer a question of whether we want to live longer, but rather, how can we use our current resources to help us achieve that goal. “Lifespan is one thing, but it is more important that we live well,” says Dr. Hans Keirstead, Chairman of Immunis. People don’t just want to live to 100, they want to thrive in their later years. Lucky for us, in this era, we have the tools.
We have “the ability to solve problems in new ways using some of these pretty magical forms of technologies,” says Dr. Kraft, a Stanford- and Harvard-trained physician-scientist and Board Member of Immunis. “From personal genomics, to wearables, to big data, to AI, to nanotech and synthetic biology,” people can take advantage of these tools to maximize their health. For over two decades, Dr. Kraft has been at the forefront of innovations in healthcare and medicine with his pioneering work in digital wellness. As the founder of Exponential Medicine, he has significantly contributed to the discourse on extending healthy lifespan, integrating cross-disciplinary technologies to reshape and understand human health.
Jane Metcalfe compares the potential impact of the current “Neobiological Revolution” to that of the digital revolution of the '90s. The visionary co-founder of WIRED magazine has emerged as a pivotal figure in the longevity arena. Her latest venture, proto.LIFE, focuses on how we are “engineering our own health” with technology. Through her influential network and thought leadership, she has become a driving force in shaping the dialogue around the scientific, ethical, and cultural implications of living longer and healthier lives.
When it comes to taking control of our health, the message is clear. The tools are available.
The time is now.
Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/.
Cautionary Note Regarding Forward-Looking Statements
This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.
